A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-023-01632-2 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Andras Nagy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Immunoglobulin G. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, a Takeda company.
Abstract (Originalsprache)
Purpose
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 20% will allow reduced infusion volumes and frequency versus existing subcutaneous therapies such as fSCIG 10% and conventional subcutaneous immunoglobulin 20%, respectively. We assessed the tolerability, safety, and immunogenicity of warmed and unwarmed fSCIG 20%.
Methods
This phase 1, single-dose, open-label, three-arm study enrolled healthy adults aged 19–50 years (inclusive) at a single US center (NCT05059977). Post-screening, participants received a single fSCIG 20% dose comprising recombinant human hyaluronidase and varying doses of in-line warmed or unwarmed immunoglobulin G (IgG) during a 4-day treatment period in a sentinel and sequential dosing design (treatment arm 1, warmed IgG 20% 0.4 g/kg; treatment arm 2, warmed IgG 20% 1.0 g/kg; treatment arm 3, unwarmed IgG 20% 1.0 g/kg). Participants were followed for 12 (± 1) weeks post-infusion. The primary endpoint was tolerability (“tolerable” infusions were not interrupted, stopped, or reduced in rate owing to fSCIG 20%-related treatment-emergent adverse events (TEAEs)). Secondary endpoints included occurrence of TEAEs.
Results
Overall, 24 participants were included, 8 per treatment arm (mean age 39.0 years, 54.2% men). All participants tolerated the infusions. All TEAEs were mild (107 events, in all participants), and all participants experienced fSCIG 20%-related (105 events) and local (102 events) TEAEs. Infusion site erythema and infusion site swelling were most frequently reported. No serious TEAEs occurred, and no participants discontinued the study owing to TEAEs. Conclusion fSCIG 20% was well-tolerated with a favorable safety profile in healthy adults. Future studies will evaluate fSCIG 20% in primary immunodeficiency diseases. Trial registration number (ClinicalTrials.gov): NCT05059977 (registered 28 September 2021).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
- Takeda Development Center Americas, Inc., Cambridge, MA, USA.
- Clinical Pharmacology of Miami, LLC, an Evolution Research Group portfolio company, Miami, FL, USA.
- University of California, Irvine, CA, USA.
- Takeda Development Center Americas, Inc., Cambridge, MA, USA. zhaoyang.li@takeda.com.
ORCID-Profile: Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Leman Yel, Zhaoyang Li
Förderung
- Takeda Development Center Americas, Inc.
- Baxalta Innovations GmbH, a Takeda company
Zitieren
APA
Nagy, A., Duff, K., Bauer, A., Okonneh, F., Rondon, J. C., Yel, L., & Li, Z. (2024). A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-023-01632-2
Vancouver
Nagy A, Duff K, Bauer A, Okonneh F, Rondon JC, Yel L, et al. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-023-01632-2
BibTeX
@article{Nagy2024,
author = {Nagy, Andras and Duff, Kimberly and Bauer, Alexander and Okonneh, Fred and Rondon, Juan Carlos and Yel, Leman and Li, Zhaoyang},
title = {A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-023-01632-2}
}
EUVIMED